Analyst Stock Ratings Downgrades

Analyst downgrades are often a bearish signal for a stock. When an analyst downgrades a stock it means the stock rating is lower than it previously was and the analyst likely does not recommend people buy the stock. Updated 09/19/2024

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating Downgrades News

Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price target.
BMO Capital Reiterates Outperform on Avery Dennison, Lowers Price Target to $252
BMO Capital analyst John McNulty reiterates Avery Dennison (NYSE:AVY) with a Outperform and lowers the price target from $254 to $252.
BMO Capital Maintains Outperform on Rogers Communications, Raises Price Target to $70
BMO Capital analyst Tim Casey maintains Rogers Communications (NYSE:RCI) with a Outperform and raises the price target from $67 to $70.
Cantor Fitzgerald Maintains Overweight on Progyny, Lowers Price Target to $25
Cantor Fitzgerald analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $37 to $25.
BMO Capital Maintains Market Perform on BCE, Raises Price Target to $51
BMO Capital analyst Tim Casey maintains BCE (NYSE:BCE) with a Market Perform and raises the price target from $48 to $51.
Cantor Fitzgerald Reiterates Overweight on CrowdStrike Holdings, Maintains $350 Price Target
Cantor Fitzgerald analyst Yi Fu Lee reiterates CrowdStrike Holdings (NASDAQ:CRWD) with a Overweight and maintains $350 price target.
BMO Capital Reinstates Market Perform on Parex Resources, Announces C$13 Price Target
BMO Capital analyst Jeremy Mccrea reinstates Parex Resources (TSX:PXT) with a Market Perform and announces C$13 price target.
RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price target.
JP Morgan Maintains Neutral on Getty Realty, Raises Price Target to $33
JP Morgan analyst Anthony Paolone maintains Getty Realty (NYSE:GTY) with a Neutral and raises the price target from $31 to $33.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free